Compare Cytokinetics Inc (CYTK) vs Taskus Inc (TASK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Taskus Inc — how do they compare? Cytokinetics Inc trades at $76.67 (market cap $10.78B), while Taskus Inc trades at $6.91 (market cap $650.52M). The key difference: Cytokinetics Inc is far larger — about 16.6× Taskus Inc's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Taskus Inc nearer its low. Which is the better fit depends on your goals.
| CYTK | TASK | |
|---|---|---|
Market Cap | $10.78B | $650.52M |
Sector | Technology | Technology |
52-Week High | $87.26 | $18.21 |
52-Week Low | $33.23 | $4.57 |
Enterprise Value | $10.88B | $1.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $76.76, down 5.67% today, with a bearish technical signal and negative profitability metrics. Recent Q2 2026 earnings beat EPS estimates but missed on revenue, while the company's drug Myqorzo shows strong commercial uptake and regulatory approvals in the UK. Cash flow remains negative from operations, offset by financing activities.
The outlook is mixed: strong analyst buy ratings (97%) and a $111.14 price target suggest upside, but high cash burn, competitive pressures, and lack of profitability pose significant risks. Investment appeal hinges on successful drug commercialization and path to profitability.
TaskUs (TASK) trades at $7.30, down 6.65% today, but maintains strong fundamentals with Q2 2026 revenue beating guidance by $10.9 million. The stock shows bullish technical signals with support at $7 and bullish moving averages. Valuation metrics appear attractive with P/E of 6.29 and P/S of 0.55, while profitability remains solid with 8.75% net margin and 25.43% ROE. Recent CFO appointment and AI services growth provide positive catalysts.
The outlook remains positive with analyst consensus favoring Buy ratings (54.55%) and improving cash flow trends. Key opportunities include undervaluation relative to earnings power and AI services expansion. Risks include client concentration and potential earnings volatility. The combination of reasonable valuation and growth momentum supports a constructive view for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →
